Tissue | Expression Dynamics | Abbreviation |
Breast | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Breast/RPS13_pca_on_diff_genes.png) | IDC: Invasive ductal carcinoma |
DCIS: Ductal carcinoma in situ |
Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/RPS13_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/RPS13_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/RPS13_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Endometrium/RPS13_pca_on_diff_genes.png) | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/RPS13_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
GC | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/GC/RPS13_pca_on_diff_genes.png) | CAG: Chronic atrophic gastritis |
CAG with IM: Chronic atrophic gastritis with intestinal metaplasia |
CSG: Chronic superficial gastritis |
GC: Gastric cancer |
SIM: Severe intestinal metaplasia |
WIM: Wild intestinal metaplasia |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/RPS13_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/RPS13_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/RPS13_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/RPS13_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/RPS13_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/RPS13_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00021819 | Breast | Precancer | cytoplasmic translation | 80/1080 | 148/18723 | 1.59e-59 | 8.54e-56 | 80 |
GO:00083809 | Breast | Precancer | RNA splicing | 65/1080 | 434/18723 | 1.27e-12 | 2.53e-10 | 65 |
GO:00434849 | Breast | Precancer | regulation of RNA splicing | 34/1080 | 148/18723 | 2.66e-12 | 4.75e-10 | 34 |
GO:00331199 | Breast | Precancer | negative regulation of RNA splicing | 9/1080 | 25/18723 | 6.03e-06 | 1.72e-04 | 9 |
GO:000218114 | Breast | IDC | cytoplasmic translation | 82/1434 | 148/18723 | 2.60e-52 | 1.48e-48 | 82 |
GO:000838014 | Breast | IDC | RNA splicing | 73/1434 | 434/18723 | 1.27e-10 | 1.57e-08 | 73 |
GO:004348414 | Breast | IDC | regulation of RNA splicing | 36/1434 | 148/18723 | 3.32e-10 | 3.77e-08 | 36 |
GO:003311914 | Breast | IDC | negative regulation of RNA splicing | 9/1434 | 25/18723 | 5.85e-05 | 1.23e-03 | 9 |
GO:000218124 | Breast | DCIS | cytoplasmic translation | 82/1390 | 148/18723 | 2.21e-53 | 1.25e-49 | 82 |
GO:000838024 | Breast | DCIS | RNA splicing | 73/1390 | 434/18723 | 3.05e-11 | 5.08e-09 | 73 |
GO:004348424 | Breast | DCIS | regulation of RNA splicing | 36/1390 | 148/18723 | 1.40e-10 | 1.69e-08 | 36 |
GO:003311924 | Breast | DCIS | negative regulation of RNA splicing | 9/1390 | 25/18723 | 4.58e-05 | 9.53e-04 | 9 |
GO:000218110 | Cervix | CC | cytoplasmic translation | 96/2311 | 148/18723 | 4.87e-51 | 2.91e-47 | 96 |
GO:004348410 | Cervix | CC | regulation of RNA splicing | 42/2311 | 148/18723 | 1.25e-07 | 6.24e-06 | 42 |
GO:003311910 | Cervix | CC | negative regulation of RNA splicing | 13/2311 | 25/18723 | 1.83e-06 | 5.89e-05 | 13 |
GO:000838010 | Cervix | CC | RNA splicing | 76/2311 | 434/18723 | 9.79e-04 | 8.19e-03 | 76 |
GO:000218115 | Cervix | HSIL_HPV | cytoplasmic translation | 86/737 | 148/18723 | 3.97e-82 | 1.91e-78 | 86 |
GO:004348415 | Cervix | HSIL_HPV | regulation of RNA splicing | 13/737 | 148/18723 | 5.72e-03 | 4.55e-02 | 13 |
GO:0002181 | Colorectum | AD | cytoplasmic translation | 109/3918 | 148/18723 | 3.40e-43 | 2.13e-39 | 109 |
GO:0008380 | Colorectum | AD | RNA splicing | 169/3918 | 434/18723 | 3.59e-18 | 2.04e-15 | 169 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0301029 | Prostate | Tumor | Ribosome | 104/1791 | 167/8465 | 3.53e-31 | 5.84e-29 | 3.62e-29 | 104 |
hsa0517129 | Prostate | Tumor | Coronavirus disease - COVID-19 | 118/1791 | 232/8465 | 3.58e-24 | 1.69e-22 | 1.05e-22 | 118 |
hsa0301037 | Prostate | Tumor | Ribosome | 104/1791 | 167/8465 | 3.53e-31 | 5.84e-29 | 3.62e-29 | 104 |
hsa0517137 | Prostate | Tumor | Coronavirus disease - COVID-19 | 118/1791 | 232/8465 | 3.58e-24 | 1.69e-22 | 1.05e-22 | 118 |
hsa0301012 | Stomach | GC | Ribosome | 64/708 | 167/8465 | 2.58e-27 | 8.26e-25 | 5.81e-25 | 64 |
hsa0517112 | Stomach | GC | Coronavirus disease - COVID-19 | 71/708 | 232/8465 | 2.32e-23 | 3.72e-21 | 2.62e-21 | 71 |
hsa0301013 | Stomach | GC | Ribosome | 64/708 | 167/8465 | 2.58e-27 | 8.26e-25 | 5.81e-25 | 64 |
hsa0517113 | Stomach | GC | Coronavirus disease - COVID-19 | 71/708 | 232/8465 | 2.32e-23 | 3.72e-21 | 2.62e-21 | 71 |
hsa0301021 | Stomach | CAG with IM | Ribosome | 63/640 | 167/8465 | 5.86e-29 | 1.86e-26 | 1.31e-26 | 63 |
hsa0517121 | Stomach | CAG with IM | Coronavirus disease - COVID-19 | 68/640 | 232/8465 | 9.36e-24 | 1.49e-21 | 1.04e-21 | 68 |
hsa0301031 | Stomach | CAG with IM | Ribosome | 63/640 | 167/8465 | 5.86e-29 | 1.86e-26 | 1.31e-26 | 63 |
hsa0517131 | Stomach | CAG with IM | Coronavirus disease - COVID-19 | 68/640 | 232/8465 | 9.36e-24 | 1.49e-21 | 1.04e-21 | 68 |
hsa0301041 | Stomach | CSG | Ribosome | 64/633 | 167/8465 | 3.70e-30 | 1.17e-27 | 8.41e-28 | 64 |
hsa0517141 | Stomach | CSG | Coronavirus disease - COVID-19 | 69/633 | 232/8465 | 8.56e-25 | 1.35e-22 | 9.74e-23 | 69 |
hsa0301051 | Stomach | CSG | Ribosome | 64/633 | 167/8465 | 3.70e-30 | 1.17e-27 | 8.41e-28 | 64 |
hsa0517151 | Stomach | CSG | Coronavirus disease - COVID-19 | 69/633 | 232/8465 | 8.56e-25 | 1.35e-22 | 9.74e-23 | 69 |
hsa0301061 | Stomach | CAG | Ribosome | 61/368 | 167/8465 | 2.85e-41 | 8.23e-39 | 6.59e-39 | 61 |
hsa0517161 | Stomach | CAG | Coronavirus disease - COVID-19 | 63/368 | 232/8465 | 7.19e-34 | 1.04e-31 | 8.32e-32 | 63 |
hsa0301071 | Stomach | CAG | Ribosome | 61/368 | 167/8465 | 2.85e-41 | 8.23e-39 | 6.59e-39 | 61 |
hsa0517171 | Stomach | CAG | Coronavirus disease - COVID-19 | 63/368 | 232/8465 | 7.19e-34 | 1.04e-31 | 8.32e-32 | 63 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
RPS13 | SNV | Missense_Mutation | | c.55C>G | p.Arg19Gly | p.R19G | P62277 | protein_coding | deleterious(0.02) | benign(0.142) | TCGA-FU-A40J-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | carboplatin | CR |
RPS13 | SNV | Missense_Mutation | | c.317N>C | p.Arg106Thr | p.R106T | P62277 | protein_coding | tolerated(0.05) | possibly_damaging(0.71) | TCGA-JW-A5VL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
RPS13 | SNV | Missense_Mutation | rs755816876 | c.111T>G | p.Ile37Met | p.I37M | P62277 | protein_coding | deleterious(0.02) | possibly_damaging(0.488) | TCGA-AA-A00N-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
RPS13 | SNV | Missense_Mutation | | c.12N>A | p.Met4Ile | p.M4I | P62277 | protein_coding | deleterious(0.03) | possibly_damaging(0.718) | TCGA-F4-6570-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
RPS13 | SNV | Missense_Mutation | | c.296N>A | p.Arg99Gln | p.R99Q | P62277 | protein_coding | tolerated(0.05) | benign(0.081) | TCGA-AX-A05Z-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | SD |
RPS13 | SNV | Missense_Mutation | novel | c.191N>A | p.Arg64His | p.R64H | P62277 | protein_coding | tolerated(0.09) | benign(0.028) | TCGA-B5-A3FC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
RPS13 | SNV | Missense_Mutation | novel | c.223N>A | p.Leu75Ile | p.L75I | P62277 | protein_coding | deleterious(0) | possibly_damaging(0.837) | TCGA-EY-A1GI-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
RPS13 | SNV | Missense_Mutation | | c.19N>T | p.Pro7Ser | p.P7S | P62277 | protein_coding | tolerated(0.21) | benign(0.006) | TCGA-WX-AA47-01 | Liver | liver hepatocellular carcinoma | Female | <65 | III/IV | Targeted Molecular therapy | sorafenib | PD |
RPS13 | SNV | Missense_Mutation | novel | c.451N>C | p.Ala151Pro | p.A151P | P62277 | protein_coding | deleterious(0) | probably_damaging(0.971) | TCGA-BA-4076-01 | Oral cavity | head & neck squamous cell carcinoma | Male | <65 | I/II | Chemotherapy | cisplatin | PD |
RPS13 | SNV | Missense_Mutation | | c.55N>G | p.Arg19Gly | p.R19G | P62277 | protein_coding | deleterious(0.02) | benign(0.142) | TCGA-CR-6481-01 | Oral cavity | head & neck squamous cell carcinoma | Male | <65 | I/II | Chemotherapy | paclitaxel | SD |